Mivria (Glucosamine Sulfate Sodium Chloride)

Glucosamine sulfate sodium chloride supplies the amino‑sugar needed for the synthesis of glycosaminoglycans, which are key components of cartilage proteoglycans. By providing this substrate, it may aid cartilage repair and modestly influence inflammatory pathways that contribute to joint degeneration.

The appropriate dose of Mivria is determined by the prescribing healthcare professional based on individual needs, age, and health status. Typical adult regimens often range around 1,500 mg per day divided into doses, but exact instructions should follow the prescriber’s guidance.

Safety data for glucosamine sulfate sodium chloride in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider to weigh potential benefits against unknown risks.

To order Mivria, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mivria provides glucosamine sulfate, which is a primary building block for cartilage. Compared with chondroitin, which supplies a different cartilage component, or MSM, which is a sulfur donor, glucosamine focuses on glycosaminoglycan synthesis. Clinical evidence varies, and many practitioners use glucosamine alone or in combination for synergistic effects.

Mivria should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Mivria is taken orally, usually with a glass of water. It can be taken with or without food, although some users find taking it with meals reduces mild gastrointestinal discomfort. Follow the dosing instructions provided by the prescriber.

Serious, though rare, risks include allergic reactions such as rash, itching, or swelling, and potential elevations in blood glucose that may affect diabetic control. Liver enzyme abnormalities and, in very uncommon cases, severe bleeding when combined with anticoagulants have also been reported.

Individuals with a known shellfish allergy should avoid Mivria, as glucosamine is often derived from shellfish. Those with severe renal impairment, uncontrolled diabetes, or who are taking anticoagulant therapy without medical supervision should also consult a healthcare professional before use.